Mumbai, India
Bristol Myers Squibb (BMS) today announced the launch of Mosaic, a new artificial intelligence–enabled content hub in Mumbai, created in collaboration with Accenture. The initiative reflects BMS’s continued investment in advanced digital capabilities to strengthen patient- and physician-focused engagement worldwide.
Mosaic is designed as an end-to-end, generative AI–powered platform that supports faster, more responsive commercialization. By using real-time insights to better understand healthcare professionals’ educational needs, the hub enables rapid development of relevant, patient-centric content at scale.
The Mumbai launch event was led by Adam Lenkowsky, Chief Commercialization Officer at Bristol Myers Squibb, alongside Ndidi Oteh, Global CEO of Accenture Song.
“Healthcare engagement is evolving toward more timely, personalized, and meaningful interactions,” said Lenkowsky. “Mosaic represents an important step in our digital transformation, helping our teams deliver the right information to healthcare professionals more efficiently, while ultimately enhancing the patient experience.”
India plays a growing strategic role in BMS’s global operations. The company has maintained a commercial presence in the country for more than 20 years and recently expanded with a major facility in Hyderabad supporting technology, drug development, supply, and enabling functions. Mosaic forms part of BMS’s broader $130 million investment in AI-driven marketing and digital initiatives, leveraging India’s strong digital talent ecosystem to scale innovation globally.
“Our mission is powered by science and strengthened by technology,” said Anvita Karara, Vice President, Worldwide Commercialization Excellence at BMS. “By integrating AI across our organization, we are improving efficiency, decision-making, and productivity—while keeping patients at the center of everything we do.”
Bristol Myers Squibb and Accenture bring more than 25 years of collaboration to the Mosaic initiative. What began as a traditional services relationship has evolved into a long-standing partnership focused on innovation, transformation, and operational excellence.
“Mosaic demonstrates how AI can meaningfully reinvent biopharma engagement,” said Ndidi Oteh, Global CEO of Accenture Song. “By combining creative talent, advanced technology, and industry expertise, this collaboration sets a new benchmark for personalized, scalable experiences for healthcare professionals.”
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for patients facing serious diseases. The company is committed to advancing science and redefining what is possible in medicine.
For more information, visit www.bms.com.
By